ArticlesInsulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis
Introduction
Insulin-like growth factors (IGFs) are multifunctional peptides that regulate cell proliferation, differentiation, and apoptosis1—attributes important in tumorigenesis. Unlike most other growth factors, IGF peptides occur in large concentrations in the circulation and have systemic, hormonal, and local paracrine effects on cell behaviour.2 In the circulation, IGF-I binds mainly to the main IGF binding protein, IGFBP-3.2 Both peptides are dependent on growth hormone, but are also affected by age (concentrations decline with age after puberty), sex, and nutritional status.3 IGF-I and IGFBP-3 concentrations vary greatly between individuals, which might affect the distribution of cancer risk in a population.4
Results of early studies on risk of prostate,5 breast,6 colorectal,7 and lung8 cancer suggested that high circulating IGF-I concentrations are associated with an increased risk of cancer, whereas high IGFBP-3 concentrations are associated with a decreased risk.9, 10 This hypothesis is supported by laboratory evidence: IGF-I is mitogenic and antiapoptotic,1 whereas IGFBP-3, conventionally thought to inhibit growth through ligand sequestration, might also be antiproliferative and proapoptotic11 through actions independent of the IGF-I receptor—properties that affect tumour development.
IGF-I and IGFBP-3 concentrations can be measured easily in blood and might be useful in assessment of cancer risk. Since the associated cancers are common (half of all malignant diseases in developed countries),12 the epidemiological observations could have major implications for public health. However, the results from studies have been inconsistent,10 and the reasons underlying heterogeneous results, including differences between cancer sites, study populations, and designs, and assay characteristics need to be investigated further. We have investigated these questions in a systematic review and meta-regression analysis.
Section snippets
Identification of studies
We searched MEDLINE and EMBASE from January, 1996, to December, 2002, to identify epidemiological studies. The search combined key words: plasma IGF* and serum IGF* with prostate cancer, breast cancer, colorectal cancer, and lung cancer. We searched specialist journals and conference proceedings by hand and searched reference lists from relevant articles, general reviews,4, 9, 10, 13 and a previously published meta-analysis in prostate cancer.14 No language restrictions were imposed.
We included
Results
From an initial 139 potentially relevant articles, we included 21 (26 datasets since breast cancer was analysed by menopausal status) in our analysis (figure 1). Six studies investigated prostate cancer,5, 22, 23, 24, 25, 26 five colorectal cancer,7, 27, 28, 29, 30 six breast cancer,6, 31, 32, 33, 34, 35 and four lung cancer.8, 36, 37, 38 Combined, these studies included 3609 cases and 7137 controls. Two additional studies39, 40 were eligible for subgroup analyses. Further details of the search
Discussion
We have systematically reviewed published epidemiological reports on the association between circulating total IGF-I and total IGFBP-3 concentrations and the risk of cancer. Higher concentrations of IGF-I were associated with prostate, colorectal, and premenopausal breast cancer, whereas higher concentrations of IGFBP-3 were associated with premenopausal breast cancer only. When modelling the dose-response relation between blood concentrations and cancer risk, associations were confirmed for
References (60)
Insulin-like growth factor physiology and cancer risk
Eur J Cancer
(2000)- et al.
Circulating concentrations of insulin-like growth factor-I and risk of breast cancer
Lancet
(1998) - et al.
Meta-analysis in clinical trials
Control Clin Trials
(1986) - et al.
Determination of IGF-I, IGF-II, IGFBP-2, and IGFBP-3 levels in serum and plasma: comparisons using the Bland-Altman method
Growth Horm IGF Res
(2003) - et al.
Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells
J Biol Chem
(2002) - et al.
Free insulin-like growth factors (IGF-I and IGF-II) in human serum
FEBS Lett
(1994) - et al.
The effects of insulin-like growth factors on tumorigenesis and neoplastic growth
Endocr Rev
(2000) - et al.
Insulin-like growth factors and their binding proteins: biological actions
Endocr Rev
(1995) - et al.
Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions
Endocr Rev
(1997) - et al.
Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study
Science
(1998)
Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3
J Natl Cancer Inst
Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis
J Natl Cancer Inst
Role of the insulin-like growth factor family in cancer development and progression
J Natl Cancer Inst
Insulin, insulin-like growth factors and colon cancer: a review of the evidence
J Nutr
Cellular actions of the insulin-like growth factor binding proteins
Endocr Rev
World cancer report
Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer
J Natl Cancer Inst
Insulin-like growth factor-I and prostate cancer: a meta-analysis
Br J Cancer
The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions
J Epidemiol Community Health
Methods for trend estimation from summarized dose-response data, with applications to meta-analysis
Am J Epidemiol
Bias in meta-analysis detected by a simple, graphical test
BMJ
High-risk colorectal adenomas and serum insulin-like growth factors
Br J Surg
Explaining heterogeneity in meta-analysis: a comparison of methods
Stat Med
Statistical methods for assessing the influence of study characteristics on treatment effects in ‘meta-epidemiological’ research
Stat Med
Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study
J Natl Cancer Inst
Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen
J Clin Endocrinol Metab
Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer
J Clin Endocrinol Metab
Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study
J Natl Cancer Inst
Insulin-like growth factors and prostate cancer: a population-based case-control study in China
Cancer Epidemiol Biomarkers Prev
A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women
Cancer Epidemiol Biomarkers Prev
Cited by (1479)
Acromegaly and Cancer: An Update
2023, Archives of Medical ResearchCombination of the biomarkers for aging and cancer? - Challenges and current status
2023, Translational OncologyObesity, obesities and gastrointestinal cancers
2023, Disease-a-MonthConnecting the dots in the associations between diet, obesity, cancer, and microRNAs
2023, Seminars in Cancer BiologyObesity is associated with biliary tract cancer mortality and incidence: A pooled analysis of 21 cohort studies in the Asia Cohort Consortium
2024, International Journal of Cancer